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OPEN
ORIGINAL ARTICLE
The significance of circulating tumor cells in prostate cancer
patients undergoing adjuvant or salvage radiation therapy
LE Lowes1,2, M Lock2,3, G Rodrigues2,3, D D’Souza2,3, G Bauman2,3, B Ahmad2,3, V Venkatesan2,3, AL Allan1,2,3 and T Sexton2,3,4
BACKGROUND: Following radical prostatectomy, success of adjuvant and salvage radiation therapy (RT) is dependent on the
absence of micrometastatic disease. However, reliable prognostic/predictive factors for determining this are lacking. Therefore,
novel biomarkers are needed to assist with clinical decision-making in this setting. Enumeration of circulating tumor cells (CTCs)
using the regulatory-approved CellSearch System (CSS) is prognostic in metastatic prostate cancer. We hypothesize that CTCs may
also be prognostic in the post-prostatectomy setting.
METHODS: Patient blood samples (n= 55) were processed on the CSS to enumerate CTCs at 0, 6, 12 and 24 months after
completion of RT. CTC values were correlated with predictive/prognostic factors and progression-free survival.
RESULTS: CTC status (presence/absence) correlated significantly with positive margins (increased likelihood of CTCneg disease;
P= 0.032), and trended toward significance with the presence of seminal vesicle invasion (CTCpos; P= 0.113) and extracapsular
extension (CTCneg; P= 0.116). Although there was a trend toward a decreased time to biochemical failure (BCF) in baseline
CTC-positive patients (n= 9), this trend was not significant (hazard ratio (HR) = 0.3505; P= 0.166). However, CTC-positive status at
any point (n= 16) predicted for time to BCF (HR = 0.2868; P= 0.0437).
CONCLUSIONS: One caveat of this study is the small sample size utilized (n= 55) and the low number of patients with CTC-positive
disease (n= 16). However, our results suggest that CTCs may be indicative of disseminated disease and assessment of CTCs during
RT may be helpful in clinical decision-making to determine, which patients may benefit from RT versus those who may benefit more
from systemic treatments.
Prostate Cancer and Prostatic Diseases (2015) 18, 358–364; doi:10.1038/pcan.2015.36; published online 4 August 2015
INTRODUCTION
In the United States in 2014, it is estimated that there will be
233 000 new cases of prostate cancer (PCa) diagnosed and 29 480
deaths from this disease.1 Upon diagnosis, one commonly
recommended treatment option is surgical resection of the
prostate via radical prostatectomy (RP).2 Following surgical
intervention, patients are monitored using PSA testing. However,
within 10 years of RP, up to 30% of early-stage patients will
experience a rise in PSA levels and require additional treatment for
residual/recurrent disease.3,4 Following relapse, evaluation of time
to biochemical recurrence, PSA doubling time and pathological
features (Gleason score, margin status, seminal vesicle invasion
(SVI) and extracapsular extension (ECE)) can assess the risk of PCa-
specific mortality. Patients will then be recommended for either
surveillance, potentially curative radiation therapy (RT) or palliative
hormonal therapy.5 Although these parameters provide a measure
of disease aggressiveness, neither they nor available imaging
technologies can determine the precise location of recurrent PCa,
thereby presenting a unique problem. If recurrent disease is
localized to the prostate bed, RT could be curative. However, if the
disease has become systemic, local radiation will be insufficient
and systemic therapy may be necessary. Therefore, novel
biomarkers that could discriminate patients with local recurrence
versus those with systemic disease would be of clinical benefit.
The presence of circulating tumor cells (CTCs) in the blood-
stream of PCa patients has been correlated with metastatic
disease.6 In addition, CTC detection in the metastatic setting is
prognostic, correlating with significantly reduced progression-free
and overall survival.6 However, given that CTCs are rare and
present in a high background of contaminating blood cells,
detection and enumeration of CTCs requires highly sensitive and
clinically reproducible assays. Currently, the only CTC analysis
platform cleared by the United States Food and Drug Adminis-
tration for prognostic use in metastatic breast, prostate and
colorectal cancer is the CellSearch System (CSS) by Janssen
Diagnostics,7 thereby making it the current gold standard in CTC
technology in the metastatic setting for these disease sites.
Using this platform, the clinical value of CTCs in metastatic PCa
has been extensively explored.6,8,9 Studies demonstrate that
patients with ⩾ 5 CTCs per 7.5 ml of blood have significantly
reduced progression-free and overall survival compared with
patients with o5 CTCs.6 In addition, changes in CTC number
throughout therapy may be a surrogate end point for treatment
efficacy in the metastatic setting.8 However, the clinical value of
CTCs in patients with localized PCa is less well described, with the
majority of studies focusing on the utility of CTCs in determining
biochemical failure (BCF) following RP. However, few have
explored the utility of CTCs in determining response to interven-
tion to treat residual disease (that is, RT).10–12
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Based on these initial reports we hypothesized that the
presence of CTCs in the blood of PCa patients undergoing
adjuvant or salvage radiation may be an indicator of disseminated
disease and may ultimately assist with clinical decision-making in
this patient cohort. In this study, we specifically assessed whether
the presence of CTCs either before or following completion of RT
(measured at baseline and 6, 12 and 24 months post-treatment)
is indicative of treatment response. To our knowledge, this is the
most extensive report in the literature examining the value of
CTCs in this uniquely challenging patient population, including
serial CTC sampling following treatment completion and the
longest period of follow-up to date (up to 3 years in some
patients). In addition, we believe we are the first to describe the
utility of CTCs in adjuvant patients undergoing RT.
MATERIALS AND METHODS
Patient population
All studies were carried out under a protocol approved by the Western
University's Health Sciences Research Ethics Board. All patients were
enrolled following informed consent. Fifty-five PCa patients who had
consented to adjuvant or salvage RT following RP were enrolled. Inclusion
criteria for adjuvant patients included the presence of any adverse
pathological findings such as ECE, positive margins and/or SVI without the
presence of a detectable PSA (o0.1 ngml− 1). Patients who were enrolled
with the intent of adjuvant radiation but who had detectable PSA
levels pre-radiation were categorized as adjuvant/salvage and analyzed
separately. Inclusion criteria for salvage patients included PSA value of
40.1 ngml− 1 (http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDe-
tails.aspx?study= 0534) and a minimum of three PSA values taken 1 month
apart, in order to calculate doubling time. Pre-RT bone scan and computed
tomography scan were performed at the discretion of the physician. Blood
was drawn before the initiation of RT to determine baseline PSA and CTC
levels. Additional baseline characteristics were noted, including Gleason
score, pathologic T (pT) stage, margin status, lymph node status, presence
Table 1. Comparison of the clinicopathologic factors and CTC status









Total 19 (34.5) 33 (60) 3 (5.5) 55 (100)
T stage
T2 2 (11) 15 (45) 0 (0) 17 (31)
T3a 15 (79) 14 (42) 3 (100) 32 (58)
T3b 2 (11) 4 (12) 0 (0) 6 (11)
Gleason score
6 1 (5) 6 (18) 0 (0) 7 (13)
7 17 (89) 25 (76) 2 (67) 44 (80)
8–10 1 (5) 2 (6) 1 (33) 4 (7)
Marginspos 12 (63) 17 (52) 2 (67) 31 (56)
ECEpos 17 (89) 18 (55) 3 (100) 38 (69)
SVIpos 2 (11) 5 (15) 1 (33) 8 (15)
CTCpos (baseline) 3 (16) 4 (12) 2 (67) 9 (16)
CTCpos (any time)a 5 (26) 9 (27) 2 (67) 16 (29)
Abbreviations: CTC, circulating tumor cell; ECE, extracapsular extension;
SVI, seminal vesicle invasion. aThe number of CTCs detected in patients
within each patient population are as follows: 1 (n= 4) and 3 (n= 1)
(adjuvant); 1 (n= 6), 2 (n= 1), 4 (n= 1) and 5 (n= 1) (salvage, with one
patients having CTCs at baseline (4 CTCs) and 12 months (1 CTC)); 1 (n= 1)
and 2 (n= 1) (adjuvant/salvage).
Figure 1. Circulating tumor cell (CTC) status at baseline correlates with previously recognized patterns of disease recurrence of the
clinicopathologic risk factors, extracapsular extension, seminal vesicle invasion and margin status. (a) Percentage of patients with CTCs absent
(CTCneg/−; n= 34) versus CTCs present (CTCpos/+; n= 4) at baseline who presented with extracapsular extension. (b) Percentage of patients with
CTCneg (n= 29) versus CTCpos (n= 2) at baseline who presented with positive margins. (c) Percentage of patients with CTCneg (n= 5) versus
CTCpos (n= 3) at baseline who presented with seminal vesicle invasion. (d) Percentage of patients with CTCneg (n= 3) versus
CTCpos (n= 1) at baseline who presented with a Gleason score of 47.
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of ECE, presence of SVI, months free from relapse, mean PSA and mean
PSA doubling time where appropriate. All patients were treated with
radiation to the prostate bed as per Radiation Therapy Oncology Group
guidelines with 6600 cGy in 33 fractions using a 5 field intensity modulated
RT technique.13 Following completion of RT, PSA levels were determined at
3, 6, 12, 18, 24, 30 and 36 months, whereas CTC levels were determined at
6, 12 and 24 months post-RT.
PSA determination and BCF
Blood samples for PSA determination were analyzed by the London Health
Sciences Centre Endocrinology Laboratory on the AutoDelfia automatic
immunoassay system (Perkin Elmer, Waltham, MA, USA) using a time-
resolved fluoroimmunoassay. BCF following RT was defined as three
consecutive rises in PSA during follow-up.
CTC enumeration
All blood samples for CTC analysis were drawn into CellSave tubes
(Janssen, Raritan, NJ, USA) and analyzed within 96 h.14 CTCs were identified
as being selected by anti-EpCAM (epithelial cell adhesion molecule),
positive for cytokeratin (8/18/19) and the DNA stain 4′, 6-diamidino-2-
phenylindole (DAPI), 44 μm diameter and with an intact cell membrane.
CTC results were analyzed by two independent and blinded observers and
enumerated using the criteria described above. A positive CTC result was
defined as ⩾ 1 CTCs per 7.5 ml of blood.
Statistical analysis
Comparisons were made between patients with CTCs at baseline (CTCpos),
versus those without CTCs (CTCneg). A two-tailed Fisher's exact test was
used to analyze differences between CTCpos and CTCneg groups relative to
Gleason score (47), SVI, margin status, ECE, radiation type (salvage,
adjuvant or adjuvant/salvage) and BCF at 2 years. Unpaired t-tests were
used to assess age differences between CTCpos and CTCneg groups. Log-
rank tests were utilized to examine time to BCF.
RESULTS
Fifty-five PCa patients from the adjuvant or salvage settings were
enrolled in the study. Of these, 19 (34.5%) were classified as
adjuvant, 33 (60%) as salvage and 3 (5.5%) as adjuvant/salvage.
The clinicopathological risk factors (CRFs) of study patients are
presented in Table 1. Mean pre-radiation PSA (and range) was
observed to be 0.33 (0.11–1.37; salvage setting) and 0.42 (0.11–1.0;
adjuvant/salvage setting). Mean PSA doubling time (and range)
was 16.4 (2–78) months (only measured in salvage patients). No
correlation was observed between PSA levels and CTC status
(presence/absence).
To determine the relationship between CTCs at baseline and
CRFs, patients were characterized as either CTCneg (0 CTCs; n= 46)
or CTCpos (⩾1 CTCs; n= 9; Figure 1 and Supplementary Table 1). No
significant differences were observed for patients with a Gleason
score of 47 and CTCneg (n= 3) versus CTCpos (n= 1) status at
baseline (P40.05). However, a trend toward statistical significance
was observed when considering the presence of ECE (P= 0.116) or
SVI (P= 0.113). For CTCneg patients, there was a trend toward the
presence of ECE, with 73.9% presenting with ECE (n= 34) versus
44.4% of CTCpos patients (n= 4). However, when considering SVI
the opposite trend was observed, with 10.9% of CTCneg patients
presenting with SVI (n= 5) versus 33.3% of CTCpos patients (n= 3).
A statistically significant difference was observed in relation to
Figure 2. Circulating tumor cell (CTC) status at any time point correlates with previously recognized patterns of disease recurrence of the
clinicopathologic risk factor, margin status. (a) Percentage of patients with CTCs absent (CTCneg/-; n= 29) at all time points versus CTCs present
(CTCpos/+; n= 9) at any time point who presented with extracapsular extension. (b) Percentage of patients with CTCneg (n= 25) at all time
points versus CTCpos (n= 6) at any time point who presented with positive margins. (c) Percentage of patients with CTCneg (n= 4) at all time
points versus CTCpos (n= 4) at any time point who presented with seminal vesicle invasion. (d) Percentage of patients with CTCneg (n= 3) at all
time points versus CTCpos (n= 1) at any time point who presented with a Gleason score of 47.
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margin status (P= 0.032), with 63.0% of CTCneg patients presenting
with positive margins (n= 29) versus 22.2% of CTCpos patients
(n= 2).
In addition to CTC status at baseline, analysis was also
performed to determine the relationship between detectable
CTCs at any time point and CRFs. Patients were characterized as
either CTCneg (n= 39) at all time points or CTCpos (n= 16) at
any time point, including at baseline (Figure 2 and Supplementary
Table 2). No significant differences were observed when
considering ECE, SVI or Gleason score of 47 and CTCneg (n= 29,
4 and 3, respectively) versus CTCpos (n= 9, 4 and 1, respectively)
status (P40.05). However, a trend toward statistical significance
was observed when considering margin status (P= 0.083). For
CTCneg patients, there was a trend toward the presence of positive
margins, with 64.1% of CTCneg patients presenting with positive
margins (n= 25) versus 37.5% of CTCpos patients (n= 6), similar to
that observed for CTC status at baseline.
Ultimately, the usefulness of CTCs in this patient cohort
depends on their ability to determine who will experience BCF
and who will not. Therefore, patients were divided into those with
CTCs absent (n= 45) or present (n= 9) at baseline and log rank
analysis was utilized to assess differences in time to BCF in these
patient subgroups (Figure 3a). Although there was a trend toward
a decreased time to BCF in baseline CTCpos patients, this trend was
not significant (P= 0.166). Similar analysis was then performed on
patients subdivided as CTCneg at all time points (n= 38) versus
those who were CTCpos at any time point (n= 16). The results
demonstrated a significantly decreased time to BCF in CTCpos
patients (P= 0.043; Figure 3b). No significant difference was
observed in BCF at 2 years in patients with CTCneg versus CTCpos
disease at baseline (Supplementary Table 1). However, a
significant difference was observed in BCF at 2 years when
considering patients with CTCneg versus CTCpos disease at any
time point (P= 0.049; Supplementary Table 2). No significant
difference was observed in BCF at 2 years or time to BCF between
adjuvant and salvage patient groups (Supplementary Table 3).
Although CTCs alone at baseline were not an independent
predictor of time to BCF, we investigated if combination with one
or more of the known CRFs would enhance this ability. This
approach demonstrated that patients with the presence of ECE
(Figure 4a) or SVI (Figure 4c) in combination with a CTCpos status at
baseline had a decreased time to BCF (P= 0.027 and P= 0.043,
respectively) versus those with the presence of ECE or SVI alone.
However, a significant difference was not observed when
comparing patients with the presence of positive margins and a
CTCpos status versus those with the presence of positive margins
alone (P= 0.250; Figure 4b). As the presence of negative margins
in this patient population suggests that patient’s disease may no
longer be confined to the prostate bed, time to BCF analysis was
performed to determine whether a relationship existed between
CTC status at baseline and negative margins. Based on this
analysis, no significant difference was observed between patients
with CTCneg marginneg disease and those with CTCpos marginneg
disease (data not shown).
Similar analysis was then performed on the ability of CTC status
at any time point in combination with one or more of the known
CRFs to determine time to BCF. Patients who presented with
one or more CRFs were subdivided into those who were either
CTCpos versus CTCneg at any time point. This further demonstrated
the relationship between the ability of CTCs to determine time to
BCF in patients in combination with the presence of ECE (P= 0.025;
Figure 5a), although the same was not observed in combination
with the presence of SVI (P= 0.128; Figure 4c). However, a
significant relationship was observed when comparing patients
with the presence of positive margins and CTCpos status at any
time point versus those with the presence of positive margins
alone (P= 0.001; Figure 5b). In addition, a very strong relationship
was observed with the combination of presence of positive
margins and ECE and CTCpos status at any time point versus those
with the presence of positive margins and ECE alone (Po0.0001;
Figure 5d).
DISCUSSION
Current imaging technologies cannot differentiate local from
systemic failure following RP. Regardless, RT is a common
treatment option, as biomarkers that can distinguish those who
will benefit from RT versus those who will not are unavailable.
Unfortunately, for patients whose cancer has become systemic,
RT will not provide benefit, resulting in up to 30% of patients
experiencing disease recurrence. Therefore, novel biomarkers that
could distinguish these patient groups before initiation of RT is
essential. To the best of our knowledge, only two published
studies have explored CTCs in this patient population. The first
was performed in a small number of patients (n= 15) using a non-
standardized reverse-transcription PCR approach examining the
detection of PSA mRNA in the blood.12 This study suggested that
the presence of PSA mRNA following RP was indicative of
micrometastatic disease and may predict poor response to
salvage RT. The second study, published by our group, was the
first to explore the detection and enumeration of CTCs using the
Food and Drug Administration-cleared CSS.14 This study demon-
strated that CTCs were detectable in salvage patients (n= 26)
using the CSS, and that, similar to metastatic disease, changes in
CTC number following RT may be indicative of treatment
response. In the current study, we sought to determine whether
detection of CTCs before initiation of RT could be utilized as a
Figure 3. CTCpos status at baseline and at any time point correlates
with a decrease in time to biochemical failure following adjuvant or
salvage radiotherapy. (a) Percentage of patients with circulating
tumor cells (CTCs) absent (CTCneg/-; n= 45) versus CTCs present
(CTCpos/+; n= 9) at baseline who are biochemical failure free over a
36-month period. (b) Percentage of patients with CTCneg (n= 38) at
all time points versus CTCpos (n= 16) at any time point who are
biochemical failure free over a 36-month period.
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surrogate biomarker for disseminated disease and therefore an
indicator of treatment failure in this patient cohort.
Despite having only a small number of CTCpos patients before
RT, strong correlations were observed with regards to CTC status
at baseline and known CRFs. Interestingly, CTCneg disease was
most highly correlated with CRFs associated with local recurrence,
including ECE and positive margins.15 However, when considering
SVI, a CRF associated with systemic relapse,15 a correlation with
CTCpos disease was observed. These correlations, although in
opposite directions, are consistent with the clinical observations of
local versus systemic relapse associated with these CRFs. Based on
the propensity for local relapse in ECE+ and margin+ patients, we
would anticipate that these patients would exhibit a tendency
toward non-disseminated and therefore CTCneg disease versus
SVI+ patients, known to have a propensity for systemic relapse,
whom we would anticipate would exhibit a tendency toward
disseminated and therefore CTCpos disease. Therefore, CTC status
appears to be in agreement with existing CRFs, suggesting that
CTCs may relate to disease localization in these patients.
Although these associations suggest a relationship between
CTCs and disease spread, the value of CTCs in this patient cohort
will depend on their ability to predict RT success. Upon
examination of BCF at 2 years and time to BCF, we noted a
strong trend toward reduced time to BCF in CTCpos versus CTCneg
patients at baseline. However, this trend was statistical significant
when considering patients with CTCs at any time point for both
measures (BCF at 2 years and time to BCF). These promising results
suggest that the detection of CTCs at any time may be a surrogate
biomarker of metastatic disease, and support a recommendation
for early initiation of systemic treatment in this patient cohort.
However, this study also aimed to determine whether CTCs
could predict the outcome of RT before treatment initiation,
thereby reducing radiation-induced morbidity in patients for
which benefit would not be achieved. Therefore, CTC status at
baseline was examined in combination with known CRFs to
determine whether this approach could improve our ability to
discriminate these patient subsets. We have demonstrated that
the presence of ECE or SVI in association with CTCpos status at
baseline is predictive of poorer response to RT. However, as this
study was not powered appropriately to determine definitive
associations between combinations of CRFs and CTCs, not all
significant associations observed at baseline were significant
when considering CTC status at any time point and vice versa. In
addition, not all CRF combinations, especially multiple CRFs (for
example, ECE + SVI + CTC), could be effectively examined. How-
ever, the results presented here, specifically with regards to ECE
and CTC status, demonstrate consistently poorer outcomes
following RT, further strengthening the existence of a relationship
between the presence of CTCs and disease spread. This suggests
that the addition of CTCs to a patient’s clinicopathologic ‘risk
profile’ (ECE, SVI and margin status) may further enhance our
ability to discriminate patients with localized versus systemic
recurrence. Further studies that could elucidate such risk profiles
are justified.
The sample size for this study was chosen based on our pilot
studies, which demonstrated that over 70% of salvage patients
presented with CTCs at baseline using the CSS.14 Unfortunately, in
the current study, only 16% of salvage patients and 12% of
adjuvant patients presented with CTCs. Interestingly, for patients
in the adjuvant/salvage group, 67% had detectable CTCs at
Figure 4. Combination of circulating tumor cell (CTC) status at baseline and known clinicopathologic risk factors, extracapsular extension (ECE)
or seminal vesicle invasion (SVI), can predict for time to biochemical failure following adjuvant or salvage radiotherapy. (a) Percentage of
patients who are biochemical failure free over a 36-month period and who presented with ECE, but without CTCs (CTCneg/-; n= 34), versus
patients with ECE, but with CTCs (CTCpos/+; n= 4), at baseline (P= 0.027). (b) Percentage of patients who are biochemical failure free over a
36-month period and who presented with positive margins (margins), but CTCneg (n= 29), versus patients with positive margins, but CTCpos
(n= 2), at baseline (P40.05). (c) Percentage of patients who are biochemical failure free over a 36-month period and who presented with SVI,
but CTCneg (n= 5), versus patients with SVI, but CTCpos (n= 3), at baseline (P= 0.043).
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baseline and all demonstrated treatment failure within 18 months,
suggesting that CTCs may be more readily detectable and
particularly valuable in these rapidly progressing patients. How-
ever, these results would require confirmation in a larger follow-up
study. In agreement with our pilot analysis,14 the majority of
patients with detectable CTCs at baseline presented with o2
CTCs (67%), and no patient had 45 CTCs at any point. Although
the CSS can detect as few as 1 CTC per 7.5 ml of blood, variability
increases significantly as the number of CTCs approaches 0, and
with such low rates of detection the potential for false negative/
positive results cannot be discounted as a confounding factor
of this study. Therefore, proper enumeration of CTCs in these
patients may be difficult and likely contributed to the high
number of CTCneg patients at baseline that failed RT (66%). The
low number of CTCs observed throughout the course of this study
presents a statistical challenge that can be overcome by either
increasing sample size, increasing CTC capture by collecting
additional blood for analysis (47.5 ml) or utilizing new emerging
CTC technologies with increased sensitivity.16 In doing so, analysis
of changes in CTC number at baseline compared with a
subsequent post-treatment time points may be possible. This
measure may also be valuable in determining the origin of
disseminating disease (that is, CTCs). For example, if CTC numbers
decrease following RT, then this may indicate that the residual
disease was localized to the prostate bed and effectively treated
using RT. However, should CTC numbers remain unchanged or
increase following RT this may be an indicator of metastatic
disease.
In summary, we believe the results presented here are the first
to demonstrate that CTC enumeration using the clinical gold
standard CTC analysis CSS platform may be valuable in clinical
decision-making to determine which patients should receive RT
versus those who would benefit more from systemic therapy.
Validation studies using larger patient cohorts to examine the
clinicopathologic 'risk profiles' outlined in this manuscript are
necessary and justified based on these novel results.
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